Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Huntington's Disease Therapeutics Market 2017-2021 - Early Onset of Disease Symptoms, Increases the Demand for HD Therapeutics - Research and Markets

Research and Markets
Posted on: 22 Aug 17

The "Global Huntington's Disease Therapeutics Market 2017-2021" report has been added to Research and Markets' offering.

The global huntington's disease therapeutics market to grow at a CAGR of 14.75% during the period 2017-2021

The global HD therapeutics market was witnessing a high unmet demand for disease modifying drug, in the presence of only one approved therapy, Xenazine, and the off-label use of various different therapeutics. The introduction of AUSTEDO in the market will have a significant impact on the market growth, thereby changing the market dynamics. To calculate the market size, the report considers sales of branded, generic, and off label drugs. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is advances in biomedical sciences. In the past few decades, the advancement in science and introduction of nanotechnologies in the global pharmaceutical market, have revolutionized the development of medicines. With better understanding of the pathogenesis of disease at genetic and molecular level have led to the discovery of new targets for therapy, thus producing disease modifying drugs.

According to the report, one driver in the market is early onset of disease symptoms, increases the demand for HD therapeutics. The prevalence rate of HD is equal in both males and females, and the disease affects humans of all ethnic and racial groups. The disease symptoms first appear in the mid-life, between the ages of 25-45 years.

Further, the report states that one challenge in the market is increase in alternative programs for management of mental disorders. The currently available HD therapeutics are unsuccessful in eliminating the symptoms of most of the mental disorders and are known to cause severe side effects such as weight gain, sedation, prolongation of the corrected QT (QTc) interval, and fatal blood dyscrasias.

Key Vendors

  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Prana Biotechnology
  • Teva Pharmaceutical Industries

Other Prominent Vendors

  • Intellect Neurosciences
  • Horizon Pharma
  • Sangamo Therapeutics
  • Vertex Pharmaceuticals

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Hd: An Introduction

Part 06: Market Landscape

Part 07: Pipeline

Part 08: Market Segmentation By Drug-Class

Part 09: Geographical Segmentation

Part 10: Decision Framework

Part 11: Drivers And Challenges

Part 12: Market Trends

Part 13: Vendor Landscape

Part 14: Key Vendor Analysis

Part 15: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/btlrkc/global

View source version on businesswire.com: http://www.businesswire.com/news/home/20170822005514/en/

Business Wire
www.businesswire.com

Last updated on: 22/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.